TABLE 2.

Relative gene expression (fold change in gene expression) of miR-21-5p and miR-92a-3p according to different patient’s clinical and tumoral characteristics.

Variable	miR-92a-3p	p-Value	miR-21-5p	p-Value
A: miR relative expression levels according to clinical characteristics
(HCC and LC cases)
Age > 60 years	1.06 ± 1.37		37.12 ± 68.17
Age < 60 years	0.69 ± 0.67	0.4	29.07 ± 39.86	0.71
Male	0.85 ± 1.07		23.36 ± 34.92
Female	0.93 ± 1.19	0.74	46.25 ± 74.82	0.64
VHC etiology	0.89 ± 1.32		29.53 ± 52.51
Non-HCV etiology	0.88 ± 0.91	0.96	36.11 ± 61.66	0.33
HBV etiology	0.69 ± 0.75		38.04 ± 69.54
Non-HBV etiology	0.98 ± 1.26	0.5	30.56 ± 50.7	0.36
HDV etiology	0.86 ± 0.83		28.6 ± 38.91
Non-HDV etiology	0.89 ± 1.16	0.34	33.87 ± 60.30	0.68
Abnormal INR (>1.27)	1.15 ± 1.1		20.56 ± 32.47
Normal INR	0.75 ± 1.11	0.11	40.39 ± 65.69	0.18
Low albumin (<3.5 g/dl)	0.92 ± 0.95		29.29 ± 40.46
Normal albumin	0.86 ± 1.25	0.12	37.28 ± 68.87	0.86
Abnormal Tbil (>1.2 mg/dl)	1.07 ± 1.1		24.38 ± 59.67
Normal Tbil	0.79 ± 1.12	0.13	38.34 ± 55.35	0.16
High creatinine (>1.3 mg/dl)	0.65 ± 0.88		30.14 ± 30.79
Normal creatinine	0.91 ± 1.14	0.43	33.77 ± 58.81	0.98
MELD > 15	1.02 ± 0.93		11.47 ± 14.37
MELD < 15	0.86 ± 1.15	0.13	37.75 ± 61.07	0.11
Ascites – Yes	0.82 ± 1.02		25.96 ± 39.79
Ascites – No	0.91 ± 1.16	0.95	35.73 ± 62.79	0.87
B: miR relative expression levels according to tumoral characteristics
(HCC cases)
Single nodule	0.70 ± 1.15		45.35 ± 71.81
Multiple nodules	0.42 ± 0.30	0.89	57.44 ± 74.30	0.94
Diameter >5 cm	0.63 ± 0.75		45.09 ± 65.48
Diameter <5 cm	0.62 ± 11.1	0.77	50.55 ± 75.97	1
Outside Milan criteria	0.62 ± 0.74		39.98 ± 63.74
Within Milan criteria	0.62 ± 1.13	0.77	53.63 ± 76.73	0.47
AFP > 20 ng/ml	0.71 ± 1.26		52.51 ± 85.51
AFP < 20 ng/ml	0.52 ± 0.65	0.45	43.77 ± 56.73	0.53
AFP > 100 ng/ml	0.92 ± 1.59		34.36 ± 58.05
AFP < 100 ng/ml	0.49 ± 0.58	0.2	53.56 ± 76.18	0.3